SCHEMBL620373

SCHEMBL620373

COc1cccc(N)c1C#N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.54
ADRA2B P18089 1/20 0.54
PTGS1 P23219 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
KDM4E B2RXH2 7/20 0.44
HPGD P15428 2/20 0.44
ADORA2A P29274 2/20 0.44
ADORA1 P30542 2/20 0.44
MAPT P10636 3/20 0.43
LMNA P02545 2/20 0.43
CYP2C9 P11712 1/20 0.43
USP2 O75604 1/20 0.43
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4739158 0.85 RAB9A (0.59) ALDH1A1NPC1RAB9AKDM4EHPGD
SCHEMBL3807595 0.83 NPC1 (0.44) ALDH1A1ADRA2BPTGS1TDP1NPC1
SCHEMBL2418152 0.81 CYP1A2 (0.44) ALDH1A1ADRA2BPTGS1TDP1NPC1
SCHEMBL621074 0.81 NPC1 (0.50) ALDH1A1ADRA2BPTGS1TDP1NPC1
SCHEMBL30076288 0.80 ALDH1A1 (0.46) ALDH1A1ADRA2BPTGS1TDP1KDM4E
SCHEMBL19713015 0.80 ALDH1A1 (0.46) ALDH1A1ADRA2BPTGS1TDP1KDM4E
SCHEMBL9131541 0.80 CYP1A2 (0.53) ALDH1A1ADRA2BPTGS1TDP1NPC1
SCHEMBL31060373 0.80 AR (0.50) ALDH1A1ADRA2BPTGS1TDP1KDM4E
SCHEMBL620881 0.79 MCHR1 (0.42) ALDH1A1ADRA2BPTGS1TDP1NPC1
SCHEMBL2416172 0.79 ALDH1A1 (0.58) ALDH1A1NPC1RAB9AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583852-B2 Heterocycle derivative JW PHARMACEUTICAL CORPORATION (KR) 2026-03-24 US disclosed
EP-2603098-B1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER FIRMENICH INCORPORATED (US) 2025-08-06 EP disclosed
CN-116102495-B 1,2,3, 4-Tetrahydro-9-aminoacridine compound and application thereof 浙江工业大学 2025-03-21 CN disclosed
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 CN disclosed
US-20240190828-A1 Small Molecule Inhibitors of PBRM1-BD2 NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-06-13 US disclosed
CN-112313232-B Novel heterocyclic derivatives JW中外制药公司 2024-03-08 CN disclosed
EP-4291195-A1 SMALL MOLECULE INHIBITORS OF PBRM1-BD2 The Medical College of Wisconsin, Inc. (US) 2023-12-20 EP disclosed
CN-116969921-A Compound for inhibiting or degrading HPK1 kinase and application thereof in medicine 四川海思科制药有限公司 2023-10-31 CN disclosed
CN-116102495-A 1,2,3, 4-tetrahydro-9-aminoacridine compound and application thereof 浙江工业大学 2023-05-12 CN disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
US-4404230-A ARTICIFIAL SWEETENERS DR. KARL THOMAE GMBH (DE) 1983-09-13 US disclosed
EP-0065811-A1 Disperse azopyrimidine dyestuffs IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-12-01 EP disclosed
EP-0038458-A1 4-Hydroxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide, their salts, their preparation and their utilization Dr. Karl Thomae GmbH (DE) 1981-10-28 EP disclosed
US-4160100-A OXAMIC ACID DERIVATIVES AMERICAN HOME PRODUCTS CORPORATION (US) 1979-07-03 US disclosed
US-4054666-A Compositions and methods of treating immediate hypersensitivity reactions with thiazolyl oxamic acid derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1977-10-18 US disclosed
US-4054657-A Pyrimidinyl oxamic acids and esters, and compositions and methods for the suppression of allergic manifestations AMERICAN HOME PRODUCTS CORPORATION (US) 1977-10-18 US disclosed
US-4054661-A Pyridyl oxamic acid derivatives and use in the prevention of allergic reactions AMERICAN HOME PRODUCTS CORPORATION (US) 1977-10-18 US disclosed
US-4036837-A 2 Alkoxyoxamoyl-pyrazines AMERICAN HOME PRODUCTS CORPORATION (US) 1977-07-19 US disclosed
US-3987192-A ANTIALLERGENS AND ANTIANAPHYLAXID; 2'-CYANO-OXANILIC ACID THE UPJOHN COMPANY (US) 1976-10-19 US disclosed
US-3966965-A Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions AMERICAN HOME PRODUCTS CORPORATION (US) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190828-A1 Small Molecule Inhibitors of PBRM1-BD2 BRD2, PBRM1, BRDT ALDH1A1 4514/4885ADRA2B 2655/4885PTGS1 2551/4885
US-12583852-B2 Heterocycle derivative AR, SRD5A1, NR5A1 ALDH1A1 1733/4885ADRA2B 4126/4885PTGS1 1407/4885
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 ALDH1A1 597/4885ADRA2B 245/4885PTGS1 574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.